Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta
→ The South Korean biosimilar player Samsung Bioepis has launched a copycat of Remicade on the US market at a 35% discount to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
